Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort

d'Arminio Monforte, A; Lorenzini, P; Cozzi-Lepri, A; Mussini, C; Castagna, A; Baldelli, F; Puoti, M; ... on behalf of the Icona Foundation Study Group, .; + view all d'Arminio Monforte, A; Lorenzini, P; Cozzi-Lepri, A; Mussini, C; Castagna, A; Baldelli, F; Puoti, M; Vichi, F; Maddaloni, A; Lo Caputo, S; Gianotti, N; Antinori, A; on behalf of the Icona Foundation Study Group, .; - view fewer (2018) Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clinical Trials 10.1080/15284336.2018.1440691 . (In press).

http://ift.tt/2po2A5A